TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Life Science Investing
Eupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week Life Science Investing
Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026 Life Science Investing
Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update Life Science Investing
Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates Life Science Investing
Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference Life Science Investing
SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET Life Science Investing
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals Life Science Investing
